The CSL Limited (ASX: CSL) share price is down 0.9% to $185.78 at the time of writing after a succession of declines since September – but the S&P/ASX 200 declines are not where CSL finds itself most at home.
The one-year return on CSL shares is still 29.78%, but investors acclimatised to its consistent inclines could be excused for being slightly nervous about the CSL share price over the last two months.
For most healthcare-focused investors, CSL is the ultimate holding, with the biopharmaceutical giant considered one of the highest-quality businesses on the ASX and long-term growth in its plasma and influenza business units almost guaranteed.
The recent slow down in price is likely a response to bearishness in the overall market of late, and CSL still manages to outpace sector peer Cochlear Limited (ASX: COH) in terms of value and growth, with the Cochlear share price down today at $172.07.
ResMed Inc (ASX: RMD) is another option to consider in healthcare and its also in a share price slump right now.
When a veritable investing and entrepreneurial genius speaks, it pays to listen.
In fact, he's now preparing a $100B "war chest" to invest entirely in this "terrifying" new technology, which could spell huge profits for investors.
Motley Fool contributor Carin Pickworth has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Cochlear Ltd. and ResMed Inc. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.